The use of cholesterol-lowering reagents or other cholesterol-depleting reagents has been found to improve the TβRII/TβRI binding ratio and enhance TGF-β responsiveness, thereby promoting EMT in breast cancer [39]. The gene discussed is TGFBR2; the disease is breast carcinoma.